Doxifluridine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Doxifluridine
Accession Number
DB12947
Type
Small Molecule
Groups
Investigational
Description

Doxifluridine has been investigated for the treatment of Stomach Cancer.

Structure
Thumb
Synonyms
  • 1-(β-D-5-desoxyribofuranoxyl)-5-fluoruracil
  • 5-fluoro-5'-deoxyuridine
  • 5'-deoxy-5-fluorouridine
  • 5'-DFUR
  • Doxifluridina
  • Doxifluridinum
External IDs
RO 219738 / RO-219738
Categories
UNII
V1JK16Y2JP
CAS number
3094-09-5
Weight
Average: 246.1924
Monoisotopic: 246.065199677
Chemical Formula
C9H11FN2O5
InChI Key
ZWAOHEXOSAUJHY-ZIYNGMLESA-N
InChI
InChI=1S/C9H11FN2O5/c1-3-5(13)6(14)8(17-3)12-2-4(10)7(15)11-9(12)16/h2-3,5-6,8,13-14H,1H3,(H,11,15,16)/t3-,5-,6-,8-/m1/s1
IUPAC Name
1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-4-hydroxy-1,2-dihydropyrimidin-2-one
SMILES
C[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=C(F)C(O)=NC1=O

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
(6R)-Folinic acidThe risk or severity of adverse effects can be increased when (6R)-Folinic acid is combined with Doxifluridine.
(6S)-5,6,7,8-tetrahydrofolateThe risk or severity of adverse effects can be increased when (6S)-5,6,7,8-tetrahydrofolate is combined with Doxifluridine.
(R)-warfarinThe risk or severity of bleeding can be increased when Doxifluridine is combined with (R)-warfarin.
(S)-WarfarinThe risk or severity of bleeding can be increased when Doxifluridine is combined with (S)-Warfarin.
2-MethoxyethanolThe risk or severity of adverse effects can be increased when 2-Methoxyethanol is combined with Doxifluridine.
4-hydroxycoumarinThe risk or severity of bleeding can be increased when Doxifluridine is combined with 4-hydroxycoumarin.
5-methyltetrahydrofolic acidThe risk or severity of adverse effects can be increased when 5-methyltetrahydrofolic acid is combined with Doxifluridine.
9-(N-methyl-L-isoleucine)-cyclosporin AThe risk or severity of adverse effects can be increased when Doxifluridine is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
AbataceptThe risk or severity of adverse effects can be increased when Abatacept is combined with Doxifluridine.
AbetimusThe risk or severity of adverse effects can be increased when Abetimus is combined with Doxifluridine.
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB0060406
KEGG Drug
D01309
KEGG Compound
C12739
PubChem Compound
18343
PubChem Substance
347829090
ChemSpider
17322
BindingDB
50132295
ChEBI
31521
ChEMBL
CHEMBL1130
Wikipedia
Doxifluridine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentMalignant Neoplasm of Stomach2
4CompletedSupportive CareMalignant Neoplasm of Stomach1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility5.36 mg/mLALOGPS
logP-0.82ALOGPS
logP-0.8ChemAxon
logS-1.7ALOGPS
pKa (Strongest Acidic)6.2ChemAxon
pKa (Strongest Basic)-3.6ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area102.59 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity51.55 m3·mol-1ChemAxon
Polarizability21.06 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as 5'-deoxyribonucleosides. These are nucleosides in which the oxygen atom at the 5'position of the ribose moiety has been replaced by another atom. The nucleobases here are limited to purine, pyrimidine, and pyridine derivatives.
Kingdom
Organic compounds
Super Class
Nucleosides, nucleotides, and analogues
Class
5'-deoxyribonucleosides
Sub Class
Not Available
Direct Parent
5'-deoxyribonucleosides
Alternative Parents
Glycosylamines / Pyrimidones / Halopyrimidines / Aryl fluorides / Hydropyrimidines / Vinylogous amides / Tetrahydrofurans / Heteroaromatic compounds / Ureas / Secondary alcohols
show 9 more
Substituents
5'-deoxyribonucleoside / Glycosyl compound / N-glycosyl compound / Halopyrimidine / Pyrimidone / Aryl fluoride / Aryl halide / Pyrimidine / Hydropyrimidine / Heteroaromatic compound
show 20 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
organofluorine compound, pyrimidine 5'-deoxyribonucleoside (CHEBI:31521)

Drug created on October 20, 2016 19:32 / Updated on November 02, 2018 07:31